With the capability of inducing intense electromagnetic field, energetic charge carriers, and photothermal effect, plasmonic metals provide a unique opportunity for efficient light utilization and chemical transformation. Earth‐abundant low‐cost Cu possesses intense and tunable localized surface plasmon resonance from ultraviolet‐visible to near infrared region. Moreover, Cu essentially exhibits remarkable catalytic performance toward various reactions owing to its intriguing physical and chemical properties. Coupling with light‐harvesting ability and catalytic function, plasmonic Cu serves as a promising platform for efficient light‐driven chemical reaction. Herein, recent advancements of Cu‐based plasmonic photocatalysis are systematically summarized, including designing and synthetic strategies for Cu‐based catalysts, plasmonic catalytic performance, and mechanistic understanding over Cu‐based plasmonic catalysts. What's more, approaches for the enhancement of light utilization efficiency and construction of active centers on Cu‐based plasmonic catalysts are highlighted and discussed in detail, such as morphology and size control, regulation of electronic structure, defect and strain engineering, etc. Remaining challenges and future perspectives for further development of Cu‐based plasmonic catalysis are also proposed.

No abstract

Niemann-Pick disease type C (NP-C) is a neurovisceral lipidosis characterized by defective intracellular trafficking of cholesterol and lysosomal accumulation of unesterified cholesterol, believed to be an offending metabolite. We studied the effect of cholesterol-lowering agents on hepatic and plasma cholesterol levels in NP-C by randomly assigning 25 patients with NP-C to one of five treatment regimens containing different combinations of cholestyramine, lovastatin, nicotinic acid, or dimethyl sulfoxide (DMSO). Unesterified cholesterol content was measured in liver biopsies before and after 4 months' treatment. All drug regimens except DMSO alone reduced hepatic and plasma cholesterol levels. Toxicity was limited and did not prevent any patient from completing the study. The combination of cholestyramine, lovastatin, and nicotinic acid lowered cholesterol levels in liver and blood with minimal side effects. A controlled clinical study will be necessary to determine if this regimen influences the rate of neurologic progression.

No abstract

This study shows that, in addition to LDL, chylomicron metabolism is severely impaired in FH and that the LDL receptor is significantly involved in the clearance of post-prandial lipoproteins. Moreover, this study raises the possibility that in FH, and in other disorders in which LDL receptor expression is reduced, atherogenesis might be a post-prandial disease.